{"name":"Ribomic USA Inc","slug":"ribomic-usa-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"RBM-007","genericName":"RBM-007","slug":"rbm-007","indication":"Other","status":"phase_2"},{"name":"RBM-007 Injectable Solution","genericName":"RBM-007 Injectable Solution","slug":"rbm-007-injectable-solution","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"RBM-007","genericName":"RBM-007","slug":"rbm-007","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RBM-007 Injectable Solution","genericName":"RBM-007 Injectable Solution","slug":"rbm-007-injectable-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy Market to Surge Significantly During the - GlobeNewswire","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQdjA4NjRPMVVoaVhDdmI1M2tpb0pyWlNpd3hTLVRNT01zNXVJc3NPQUpnUUEyV1pqZWNUN2lXdFdDX3dkcUNuTklNWU9NMzNQWGFXcGtRNF94QW5BTkhnYTBqN25OTmpBUVB4YXZTalg5UnN3TkNKZTdqa0ZyM2Njc21EX1MtQ0F6Y19pVHlNeXM0R21OV3dKaU01aHNOSzRBcV9CWWlmNFlHS25hQ3R5S1VKRjQyRmZWOWE2UHNRclJEakY4X1ZLekEtNmViMkFpclRzaldDT1RVaHBoanhNbUJBVG41NUxtTE1XUGxfa3JaZXQwUW54enQ1cFN3NmtwUTJHUlR0c0tHWHRLTDFKSlNuSnlEaUNRa2JqYXk5aGZKQTdOaTk0YTVyUnpKaHRiNDQwNmJkUFFJS2dhckhpN3BxNVkzRjg?oc=5","date":"2025-11-17","type":"pipeline","source":"GlobeNewswire","summary":"Dry Age-related Macular Degeneration Market Poised for - GlobeNewswire","headline":"Dry Age-related Macular Degeneration Market Poised for","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"trial","source":"BioSpace","summary":"RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration ","headline":"RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase i","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNbjlld0stX2d6WXAzaFBZeUdEVDlpMDVQTmFSZmM1ZlZORUdnbl9zOWxUUUh4UktsS3cyNE9fZWpHQm04T2g5SHM2Z18tNjNmUFpVOXV3bzdtbnRwX3JHTEIwRktFYkRleEZfVG9ZVEpzQ28xeWlJdHVqdndIYnQ0YmdpeGJMR0xHZWlleUdCWFpyelFZcTFLTHMwQQ?oc=5","date":"2025-08-26","type":"trial","source":"BioWorld News","summary":"Ribomic’s RBM-007 ready for phase III in achondroplasia - BioWorld News","headline":"Ribomic’s RBM-007 ready for phase III in achondroplasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNbDJYSVpRVE1wZ3haQzNpNTVGajEzUjFNVjNydkpKdjFqYXBLME9ScDJqakVqel9XR0hHWGxpNk0xOU5ubGhyaGtEYnNhMHkyTFk4WXFYb0xRUzQ2R3pjc2xCZE50YjJ2SHVrcHotbncweXpOY2pRY01RTE0yOC1xaUhLUGczam45ODVQQ2MwYlY1Y3VNVXBlQl9WU09nUlQwNW1hWkEzSG5vQm5XU0M4Y1Q3Q3N0bHFMckQ0MTNLbEFmQzRRbzJtMjN5b0tjalhqWWpBd1RRLXpXLV9ncnl5amFON1NKVUVfT0c1a3kzSlpwMXpnZXAxaUd4cmtNVjJVbDRSazU0MA?oc=5","date":"2025-05-06","type":"pipeline","source":"StreetInsider","summary":"Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. - StreetInsider","headline":"Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNSF8xbF9kOFk3TzBRUzVFNVNFWGRLVFk1VUpiTXVfYWdUN3RyR2NMa1R3QTl1NnhjS0RpME84bHRzbmNieHhvd2JrZjlxazdZSDNHcVFTb3h2YW1jaEpSMjR6cGlSQldjSnJaVkE0NUNyY1FRRElpR1FUNU1Zenl5YVFSUUhmNTdOcmllbEVDZk5IV2xkbTBmcXlyUEh5eW5IZjZ2U2RhRVdSX0FqdzJ1NnNCN1dHYmJNRHk0NDNvNlNiZ0dfSjd5Z2VTaUpZb0dhU3V4a2JJel9RbllGY1E2b2c1d2tWdVh1elpFcW5WOUJfaF9tU3FLaDJ6c2UzUQ?oc=5","date":"2025-01-23","type":"trial","source":"PR Newswire","summary":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - PR Newswire","headline":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOWnFwcEFyaWluNXNacFJfeWQ2NVdsUjEzRG1YeS1TWDUzQ01vYzBtN1lSOHNZMGRjREktdEdBOWV6U2l6QUwtLTI0MVFpekxyTFM0NDZVSkJmN0RKSlZ5bWRDMnNCeWJjNGtER3hJaUE1YjdyVExDeEdEamd2Mi1LcncyTDBHdl9tdl9YWlRXSEh0ZERXVzRTMEkzbkY3V29CMmFVdW1uV2p3NHNkVmNXdE9aUDU1VGV4ZGVXeVpFVXVJY1dydjIxclA3MkFkeGlvem9SUjB0dlRFZlBlWXJ5NDFCalBpSmk5VkhpUl9fT3pHSUdGZGU1YTRhSzZwWnNMQUlCWkZLSXJGbE1mX1NZ?oc=5","date":"2024-11-19","type":"pipeline","source":"GlobeNewswire","summary":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire","headline":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}